Fate Therapeutics
Clinical trials sponsored by Fate Therapeutics, explained in plain language.
A clinical-stage biopharmaceutical company developing cellular immunotherapies for cancer and immune disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could a One-Time cell infusion tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New CAR T-Cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Ready-Made immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 study tests an experimental therapy called FT825, a type of immune cell that is made in a lab and can be given to any patient without needing to use their own cells. It is being tested in people with advanced solid tumors that have HER2 or other markers. The study wi…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC